Insider trade

CEO exercised or converted 7,500 CYTK derivative securities

Traded Aug 10, 2026 · Filed Aug 10, 2026

CytokineticsCYTK

7,500
Shares · @ $10.60

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 10, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 10, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000087

Filed / recorded

Aug 10, 2026, 9:11 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Robert I Blum

Relationship

Director, Officer

Officer title

President & CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Aug 10, 2026

Transaction code

M

Shares / units

7,500

Price per share

$10.60

Acquired / disposed

Acquired (A)

Shares owned after

385,320

Ownership form

Direct

Amendment

No

Around the same time

3,500Shares · @ $7.80

4w ago

Derivative exercise or conversion — not an open-market buy.

More Official record

Officer sold ~$264K of Cytokinetics

Automatic sale4w ago

3,500Derivative units

4w ago

Derivative exercise or conversion — not an open-market buy.

More Official record